Please Wait...

Congressman Patrick Meehan Visits Bioclinica

Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices

Bioclinica was honored to host Congressman Patrick Meehan representing the 7th Congressional District in Pennsylvania in a visit to our Audubon, Pennsylvania offices on August 28. Congressman Meehan met with Bioclinica senior leadership, including our CEO Dr. John Hubbard, who is the 2017 Chairman of the Association of Clinical Research Organizations (ACRO), joined by ACRO Executive Director Douglas Peddicord. The discussion provided a view into the biopharma industry and Bioclinica’s role in advancing drug development by employing an approach that combines science and technology.

 

 

Congressman Patrick Meehan visits with Bioclinica staff joined by ACRO Executive Director Douglas Peddicord

During his visit, Congressman Meehan also participated in a town hall gathering with staff, many of whom reside within his district covering parts of southeastern Pennsylvania. "The life sciences industry is making a significant economic impact in our region as well as important contributions globally in people's health," said Congressman Meehan. "I appreciate this opportunity to see Bioclinica's operation, innovation, and remarkable work you do in bringing new cures to people in need."

 

 

Congressman Meehan hears from Bioclinica CEO John Hubbard, PhD and other company executives about Bioclinica's contributions, leading to new cures

Dr. Hubbard recognized Congressman Meehan's ongoing support of the biopharma industry and representation on Capitol Hill saying, "We appreciate all you do in support of our challenges and opportunities in the development of new cures." One such effort was the introduction of the Domestic Research Enhancement Act of 2017 with co-sponsors Rep George Holding and G.K. Butterfield of North Carolina. The Act modernizes the research and development tax credit to recognize the essential role contract research plays in the development of new pharmaceuticals, biologics, and medical devices.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Handy guide for the pharmacovigilance folks! https://t.co/tOyQWkiNhW
bioclinica (Yesterday)
#ClinicalResearch sites, REJOICE @bioclinica SMART Submit 4 cloud rsch image mgmt /subm is here! @OutsourcPharmahttp://ow.ly/odCh30grhnY
bioclinica (Yesterday)
What's next from Bioclinica? Hear if first during #PCTrials Europe next week in Amsterdam! https://t.co/ICngaxA9mg https://t.co/SXxPj3NpD2
bioclinica (2 days ago)
Join Bioclinica's Justin Hunt on Nov. 28 in a live webinar! Find out how to overcome common hurdles in CTMS impleme… https://t.co/wHfWHtI7sj
bioclinica (3 days ago)
Another CRO seeing big gains in the sites payments process! Access the Case Study here https://t.co/jsCxhmKcLo https://t.co/LpIKEtBKtE
bioclinica (3 days ago)
Great advice from our Dir. Cardiovascular Imaging on quality imaging acquisitions & assessments in clin trials. https://t.co/OVH7pZ3SL0
bioclinica (3 days ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices